Around a quarter of a million people living with obesity will be offered the weight loss drug tirzepatide, alongside a reduced-calorie diet and increased physical activity, over the next three years, final draft guidance from the National Institute for Health and Care Excellence (NICE) has outlined. The medicine is recommended by NICE for people with a body mass index of more than 35 and at least one weight-related illness.
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.
Create a network to share documents, knowledge and best practice with your colleagues. Set up a network to keep in touch with other people in your organisation or with shared interest groups across organisational boundaries.
Networks can be open to all or available only to a closed group defined by the administrator.
Join or create a network here.
